IMULAN BioTherapeutics Prepares to Initiate Atopic Dermatitis Trials

ST. JOSEPH, MO--(Marketwire - August 05, 2009) -

IMULAN BioTherapeutics, LLC announced they are prepared to commence with regulated trials to complete work on the T-Cell Receptor peptide immunomodulator, for atopic dermatitis in dogs. Canine atopic dermatitis is a very prevalent condition in dogs, thought to affect up to 5 percent of the dog population. Clinical signs of atopic dermatitis include pruritus (itching) and an increase in topical skin infections such as staphylococcal pyoderma. The T-Cell Receptor peptides have previously shown significant improvement in dogs with severe atopic dermatitis.

T-Cell Receptor peptides target T-helper cells: immune cells that are key players in atopic and allergic dermatitis. T-helper cells are central regulators of immune function and their imbalance is implicated in a variety of disorders including atopy, asthma, stomatitis, and various infections.

Dr. Daniel Gingerich, CSO of IMULAN, stated, “We are excited to begin our final phase of work that will be used in support of a product approval. We are currently setting up multiple centers around the country to participate in our clinical program and to help acquire the necessary data for submission.”

Dr. Craig Woods, CEO of IMULAN, states, “This is an exciting time for IMULAN, a small biopharmaceutical company focused on major diseases in veterinary medicine such as allergic skin disorders. We believe our immune modulating approach will be far superior to traditional immunosuppressive drugs and advance a brand new technology platform to market.”

IMULAN develops immune regulating compounds infectious, autoimmune, and immune mediated diseases in small and large animal medicine. For more information about IMULAN, please visit www.IMULAN.com

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: dermatitis T-Cell Receptor peptides alergic dermatitis atopy asthma stomatits Canine dog